Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

UroGen Pharma (URGN) EBITDA (2017 - 2025)

UroGen Pharma (URGN) has disclosed EBITDA for 9 consecutive years, with -$26.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA rose 30.04% year-over-year to -$26.4 million, compared with a TTM value of -$153.5 million through Dec 2025, down 21.05%, and an annual FY2025 reading of -$153.5 million, down 21.05% over the prior year.
  • EBITDA was -$26.4 million for Q4 2025 at UroGen Pharma, up from -$33.3 million in the prior quarter.
  • Across five years, EBITDA topped out at -$21.9 million in Q3 2023 and bottomed at -$49.9 million in Q2 2025.
  • Average EBITDA over 5 years is -$30.2 million, with a median of -$28.5 million recorded in 2021.
  • The sharpest move saw EBITDA soared 30.97% in 2021, then tumbled 49.56% in 2025.
  • Year by year, EBITDA stood at -$28.5 million in 2021, then decreased by 1.19% to -$28.8 million in 2022, then rose by 10.24% to -$25.9 million in 2023, then crashed by 45.7% to -$37.7 million in 2024, then soared by 30.04% to -$26.4 million in 2025.
  • Business Quant data shows EBITDA for URGN at -$26.4 million in Q4 2025, -$33.3 million in Q3 2025, and -$49.9 million in Q2 2025.